Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer

CONCLUSIONS: Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.PMID:33820779 | DOI:10.1158/1078-0432.CCR-20-4131

Source: Clinical Cancer Research - April 6, 2021 Category: Cancer & Oncology Authors: Bora Lim David A Potter Mohamad A Salkeni Paula Silverman Tufia C Haddad Frederic Forget Ahmad Awada Jean-Luc Canon Michael Danso Alain Lortholary Hugues Bourgeois Elizabeth Tan-Chiu Sylvie Vincent Brittany Bahamon Kevin J Galinsky Chirag Patel Rachel Neu Source Type: research